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COST OF CHRONIC BRONCHITIS (CB) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN FRANCE: THE BRONCHECO STUDY
Huchon
6 Hopital Bichat, France OBJECTIVES: To describe the management of CB and COPD at stages 1 to 3 (SPLF classification, 1997) and to assess its cost in France. METHODS: In total, 409 CB and COPD patients were enrolled in the Broncheco cohort from November 2000 to October 2003 by 10 hospital chest physicians (HP), 50 private chest physicians (PP) and 63 general practitioners (GP). The cohort was followed for 1 year with data collection every 3 months: socio-demographic data, medical history and disease management (medication, oxygen, medical visits, medical procedures, hospitalisations and transportation). Inpatient costs were evaluated using the French Diagnosis-Related Groups and outpatient costs using the French nomenclature. Costs were expressed in 2003 Euro, according to the French societal perspective. Non-parametric statistical analysis was performed. RESULTS: In total, 316 patients were analysed (random dropout was tested) with a mean age of 65 years, a history of the disease of 8 years, 75% were male and 37% were current smokers. The distribution in stages was: 21.5%, 42.1%, 22.8% and 13.6% respectively in stages 1, 2a, 2b, and 3. The annual cost (both medical and non-medical) was 794€, 1936€, 3938€ and 7706€ respectively for stages 1, 2a, 2b and 3 (p < 0.001). The proportion of outpatient care in total cost decreased when stage of disease increased (94%, 70%, 63% and 62% respectively) while the proportion of inpatient care increased (6%, 30%, 37%, 38% respectively). For a same stage of disease, the costs were higher for HP, lower for PP and the lowest for the GP. Bergmannsheil Hospital, University of Bochum, Bochum, Germany; 2 Institute of Empirical Health Economics, Burscheid, Germany; 3 Bayer Vital, Leverkusen, Germany OBJECTIVES: Inpatient treatment of community-acquired pneumonia (CAP) is generally non-invasive and therefore the financial burden for hospitals is dependent from length-of-stay. A fast recovery of the patients shows the need of rapid acting antibiotic treatment, especially under the German DRGreimbursement system. This study investigated costs and charges of patients with CAP from the hospitals' perspective. The new gyrase inhibitor moxifloxacin was compared to standard antimicrobial therapy of the participating hospitals. METHODS: The observational study was conducted prospectively in a parallel group design. In 22 hospitals, 580 patients were enrolled, 261 patients in the moxifloxacin-(M-)cohort and 319 patients in the standard-(S-)cohort of other antibiotics. The economic perspective of a German hospital was applied for the cost measurement. After conduct of the study, the patient data were grouped into the relevant German DRG and the course of treatment, costs and reimbursement of both cohorts were analysed. RESULTS: The outcome of the patients at the beginning of treatment was comparable in both cohorts. The length-of-stay of the patients was significantly shorter in the moxifloxacin cohort for the more severe DRGs E62A (M-cohort 10.1 days, N = 113; S-cohort 12.2 days, N = 164; p = 0.004) and E62B (M-cohort 9.7 days, N = 112; S-cohort 10.7 days, N = 146; p = 0.041). In the third DRG E62C no differences were found (M-cohort 10.2 days, N = 36; S-cohort 9.4 days, N = 9; p = 0.306). Net profit per case for the hospitals in the DRG E62A was 1931€ and 1683€ for the cohorts M and S respectively (E62B: M 1365€, S 1296€; E62C: M 802€, S 791€). CONCLUSIONS: For the treatment of hospitalised CAP the study demonstrated the economical relevance of fast recovery secondary to efficacious drug therapy. Under current reimbursement modalities the treatment with moxifloxacin is more profitable from the hospitals' perspective due to a shortened length of stay of the patients. 3 Bayer Vital, Leverkusen, Germany OBJECTIVES: Since the beginning of 2004, the diagnosis-relatedgroups (DRG) are implemented in the reimbursement procedure for German hospitals representing a significant change for the hospitals economic situation. As an example for non-invasive treatment procedures in a German hospital, a prospective health economic study evaluated the treatment costs of communityacquired pneumonia (CAP) from the hospital's perspective. Results of an interim analysis were published in 2003, now the final results of the study are presented. METHODS: Open, nonrandomized prospective observational study from the perspective of the German hospital administration. In 11 study centres, 319 patients were enrolled. A process-cost-analysis was performed to determine the costs for the German hospital sector starting from the admission up to the discharge of the patient. The cost calculation comprises diagnostic and therapeutic measures, drugs, hotel costs and nursing. Both personnel costs and material costs were included. Acquisition of medical devices was not included into the analysis. RESULTS: The patients enrolled suffered from moderate to severe stages of CAP with a mean length-of-stay of 11.5 days (peripheral ward: 10.7; ICU 0.8). Mean costs per patient amounted to 1528€ (SD: 1011€). Most important costdriving factors were hotel costs (640€) and nursing (554€). Drug acquisition cost resulted in 201€, whereas costs for diagnostics (80€) and therapeutic measures (54€) were comparatively low. The most often applied drugs were macrolides (37.6% of the patients), b-lactamase inhibitor-aminopenicillin combinations (32.3%), and cephalosporins of 2nd (30.4%) and 3rd generation (28.5%). Thirty-six patients (11.3%) died during the hospital stay. CONCLUSIONS: In hospitalised CAP, length of stay determines the costs from the economic perspective of the hospital, which underlines the importance of a reduction of length of stay in this indication. The need for rapid and safe antibiotic treatment becomes evident especially under consideration of the DRG reimbursement system.
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